GRAIL, Inc.
GRALHealthcareNASDAQDiagnostics & Research · Last scanned Jun 3, 2026
Scan Results
Daily timeframeGRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. Valued at $2.57B, GRAL is a mid-cap name in its sector. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.
Market Cap
$2.57B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-6.16
EPS (TTM)
$-10.30
EPS (Fwd)
$-9.72
ROE
-16.1%
ROA
-11.4%
Cash
$823.1M
Total Debt
$51.0M
Free CF
-$107.8M
52W Change
49.7%
Annual Financials
Cash vs Debt
With $823.1M in cash and $51.0M in debt, GRAL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$107.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -16.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $55.5M (2022) to $147.2M (2025), reflecting a 165% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GRAL.